Behavioral Impediments to Beneficial Experimentation-2

Last registered on July 16, 2024

Pre-Trial

Trial Information

General Information

Title
Behavioral Impediments to Beneficial Experimentation-2
RCT ID
AEARCTR-0013913
Initial registration date
July 10, 2024

Initial registration date is when the trial was registered.

It corresponds to when the registration was submitted to the Registry to be reviewed for publication.

First published
July 16, 2024, 3:28 PM EDT

First published corresponds to when the trial was first made public on the Registry after being reviewed.

Locations

There is information in this trial unavailable to the public. Use the button below to request access.

Request Information

Primary Investigator

Affiliation
FSU College of Law

Other Primary Investigator(s)

PI Affiliation
Vanderbilt University

Additional Trial Information

Status
In development
Start date
2024-07-22
End date
2024-12-31
Secondary IDs
Prior work
This trial is based on or builds upon one or more prior RCTs.
Abstract
This project explores consumers’ sensitivity to estimate precision and data quality in their willingness to experiment. Using an incentive-compatible experimental design, we measure participants’ willingness to pay for additional information about uncertain treatments and ability to update their prior beliefs based on this new information.
External Link(s)

Registration Citation

Citation
Gentry, Elissa and W. Kip Viscusi. 2024. "Behavioral Impediments to Beneficial Experimentation-2." AEA RCT Registry. July 16. https://doi.org/10.1257/rct.13913-1.0
Experimental Details

Interventions

Intervention(s)
We provide different risk data to understand participants' 1) willingness to purchase such data and 2) how they incorporate this data into their risk assessment of uncertain treatments.
Intervention Start Date
2024-07-22
Intervention End Date
2024-12-31

Primary Outcomes

Primary Outcomes (end points)
1) Determinants of the decision to purchase new information and 2) the incorporation of new information for risk perceptions by treatment group.
Primary Outcomes (explanation)

Secondary Outcomes

Secondary Outcomes (end points)
Secondary Outcomes (explanation)

Experimental Design

Experimental Design
We provide different risk data to understand participants' 1) willingness to purchase such data and 2) how they incorporate this data into their risk assessment of uncertain treatments.
Experimental Design Details
Not available
Randomization Method
Survey is administered in Qualtrics, which provides randomization services.
Randomization Unit
Individuals are randomly assigned to 5 treatment groups. Within individuals, drug characteristics and sample proportion/price are also randomized.
Was the treatment clustered?
No

Experiment Characteristics

Sample size: planned number of clusters
0
Sample size: planned number of observations
500
Sample size (or number of clusters) by treatment arms
100 per group
Minimum detectable effect size for main outcomes (accounting for sample design and clustering)
IRB

Institutional Review Boards (IRBs)

IRB Name
Florida State University
IRB Approval Date
2024-07-10
IRB Approval Number
STUDY00003405